The β-lactams have a central place in the antibacterial armamentarium, but the increasing
resistance to these drugs, especially among Gram-negative bacteria, is becoming one of the …

Managing Acinetobacter baumannii infections : Current Opinion in Infectious Diseases
Managing Acinetobacter baumannii infections : Current Opinion in Infectious Diseases Log in or …

Antibiotic resistance is a growing global concern in the field of medicine as it renders
bacterial infections difficult to treat and often more severe. Acinetobacter baumannii is a …

β-lactam antibiotics (BLAs) are crucial molecules among antibacterial drugs, but the
increasing emergence of resistance to them, developed by bacteria producing β-lactamase …

Acinetobacter baumannii is an opportunistic pathogen which is undoubtedly known for a
high rate of morbidity and mortality in hospital-acquired infections. A. baumannii causes life …

This review critically appraises the published microbiologic and clinical data on the
treatment of patients with carbapenem‐resistant Acinetobacter baumannii infections …

In multiply resistant Acinetobacter baumannii, complex transposons located in the
chromosomal comM gene carry antibiotic and heavy metal resistance determinants. For one …

Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination
in late-stage development for the treatment of Acinetobacter infections, including those …

ABSTRACT Objectives Multidrug-resistant Acinetobacter baumannii (MDR-Ab), particularly
strains producing oxacillinase (OXA)-type carbapenemases, have rapidly emerged in health …

Objectives To evaluate the activity of the novel broad-spectrum serine β-lactamase inhibitor
durlobactam (ETX2514) combined with sulbactam against global isolates of carbapenem …